Headlines about Cancer Genetics (NASDAQ:CGIX) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cancer Genetics earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.0591379446374 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern’s scoring:
Shares of NASDAQ CGIX opened at $1.20 on Friday. The company has a market capitalization of $34.69, a P/E ratio of -1.52 and a beta of 1.22. Cancer Genetics has a 1 year low of $0.90 and a 1 year high of $4.78. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.01 and a quick ratio of 2.01.
A number of research analysts have recently commented on the stock. HC Wainwright set a $6.00 target price on shares of Cancer Genetics and gave the stock a “buy” rating in a report on Tuesday, January 16th. ValuEngine raised shares of Cancer Genetics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Finally, Maxim Group lowered shares of Cancer Genetics from a “buy” rating to a “hold” rating and set a $6.00 price objective for the company. in a report on Tuesday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. Cancer Genetics has a consensus rating of “Hold” and a consensus price target of $5.56.
TRADEMARK VIOLATION WARNING: “Cancer Genetics (NASDAQ:CGIX) Given Daily News Impact Score of 0.11” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-cancer-genetics-cgix-stock-price.html.
Cancer Genetics Company Profile
Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.